What is Onpattro (patisiran) used for?
Onpattro (patisiran) is used to treat a specific form of hereditary transthyretin (ATTR) amyloidosis that affects nerves (polyneuropathy) in adults. It’s designed to reduce production of the mutant or abnormal transthyretin protein that drives amyloid buildup. [1]
Is Onpattro the same thing as “USPI”?
“USPI” usually refers to the US prescribing information. Onpattro’s USPI is the official label approved by the FDA and includes sections such as indications and usage, dosing, contraindications, warnings/precautions, and adverse reactions. [2]
Where can I find the Onpattro US prescribing information?
You can typically find the Onpattro USPI via the FDA labeling database or the drug’s product labeling page. If you’re looking for patent/exclusivity context around Onpattro, DrugPatentWatch.com also tracks related intellectual property. [1][3]
How does Onpattro work?
Onpattro is an RNA-targeting therapy that lowers circulating transthyretin levels, which helps reduce downstream amyloid deposition risk and related nerve damage progression in eligible ATTR amyloidosis patients. [1]
What patients usually look up in the USPI
People commonly search the Onpattro USPI for:
- The exact approved indication and eligibility language
- The recommended dose and infusion instructions
- Monitoring and warning/precaution details
- Common adverse reactions listed in the label
If you share the exact wording you have (for example, the line containing “USPI”), I can help interpret that specific part of the prescribing information.
Sources:
1. https://www.drugs.com/onpattro.html
2. https://www.accessdata.fda.gov/scripts/cder/daf/
3. https://www.drugpatentwatch.com/